CITI/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.24 Stock CITI/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.24
Add to a list
To use this feature you must be a member
Log inSign up

CITI/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.24 Stock

Warrant

DE000KH75JJ3

Market Closed - Deutsche Boerse AG 13:32:40 2024-06-28 EDT
0.001 EUR 0.00% Intraday chart for CITI/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.24
6 months-99.09%
Current year-99.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart CITI/CALL/BRISTOL-MYERS SQUIBB/65/0.1/19.12.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
More news

Quotes 5-day view

Date Price Change
24-06-28 0.001 0.00%
24-06-27 0.001 0.00%
24-06-26 0.001 0.00%
24-06-25 0.001 0.00%
24-06-24 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 01:32 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
IssuerLogo Issuer Citi Citi
WKN KH75JJ
ISINDE000KH75JJ3
Date issued 2023-07-18
Strike 65 $
Maturity 2024-12-19 (173 Days)
Parity 10 : 1
Emission price 0.53 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.69 €
Lowest since issue 0.001 €
Delta0x
Omega 0.000000
Premium0x
Gearing0x
Moneyness 0.6389
Difference Strike 23.47 $
Difference Strike %+36.11%
Intrinsic value 0.000000

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53 USD
Average target price
53.19 USD
Spread / Average Target
+28.09%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant